Publications by authors named "Thomas Pfister"

Claim this Profile
C
Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approach.
Claudia Sehner, Tanja Bernier, Kamila Blum, Nicole Clemann, Milica Glogovac, Thomas Pfister

Regul Toxicol Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why Language Matters in Digital Endpoint Development: Harmonized Terminology as a Key Prerequisite for Evidence Generation.
Lada Leyens, Carrie A Northcott, Lesley Maloney, Marie McCarthy, Nona Dokuzova, Thomas Pfister

Digit Biomark· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Abdulazeez Salawu, Ben X Wang, Ming Han, Caryn Geady, Alya Heirali, Thomas D Pfister

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
Luke S Howard, Stephan Rosenkranz, Robert P Frantz, Anna R Hemnes, Thomas Pfister

Chest· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.
Geoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, Zhihui Amy Liu, Sy Cindy Yang, Thomas Pfister

J Immunother Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deriving harmonised permitted daily exposures (PDEs) for paracetamol (acetaminophen) CAS #: 103-90-2.
Kamila Gromek, William Hawkins, Tanja Bernier, Claudia Sehner, Eva Zeller, Thomas Pfister

Regul Toxicol Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Environmental Risk Assessment for the Active Pharmaceutical Ingredient Mycophenolic Acid in European Surface Waters.
Jürg Oliver Straub, Rik Oldenkamp, Thomas Pfister, Andreas Häner

Environ Toxicol Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Tony Navas, Thomas D Pfister, Simona Colantonio, Amina Aziz, Lynda Dieckman

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the permitted daily exposure (PDE) concept for contaminants of intravitreal (IVT) drugs in multipurpose manufacturing facilities.
Ester Lovsin Barle, Thomas Pfister, Cornelia Fux, Dieter Röthlisberger, Dhananjay Jere

Regul Toxicol Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Adaani Frost, Munir Janmohamed, Jason S Fritz, John W McConnell, David Poch, Thomas Pfister

J Heart Lung Transplant· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study.
Maurizio Cutolo, Ariane L Herrick, Oliver Distler, Mike O Becker, Emma Beltran, Thomas Pfister

Arthritis Rheumatol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
Robert G Sussman, Bruce D Naumann, Thomas Pfister, Claudia Sehner, Christopher Seaman

Regul Toxicol Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
John F Reichard, M Andrew Maier, Bruce D Naumann, Alison M Pecquet, Thomas Pfister

Regul Toxicol Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The root causes of pharmacodynamic assay failure.
Katherine V Ferry-Galow, Hala R Makhlouf, Deborah F Wilsker, Scott M Lawrence, Thomas D Pfister

Semin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Apurva K Srivastava, Melinda G Hollingshead, Jennifer Weiner, Tony Navas, Yvonne A Evrard, Thomas D Pfister

Clin Cancer Res· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Shivaani Kummar, Alice Chen, Martin Gutierrez, Thomas D Pfister, Lihua Wang

Cancer Chemother Pharmacol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Mn(II)-Binding and Manganese Peroxidase Activity in a Designed Cytochrome c Peroxidase through Fine-Tuning Secondary-Sphere Interactions.
Parisa Hosseinzadeh, Evan N Mirts, Thomas D Pfister, Yi-Gui Gao, Christopher Mayne

Biochemistry· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Niels Frank Jensen, Keli Agama, Amit Roy, David Hersi Smith, Thomas D Pfister

J Exp Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Phytotherapy in geriatrics and gerontology].
Reinhard Saller, Siegfried Kasper, Wilfried Dimpfel, Egemen Savaskan, Thomas Pfister

Forsch Komplementmed· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of new technologies to characterization and prediction of adverse effects.
David Rouquié, Marjoke Heneweer, Jane Botham, Hans Ketelslegers, Lauren Markell, Thomas Pfister

Crit Rev Toxicol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Rozenn Jossé, Scott E Martin, Rajarshi Guha, Pinar Ormanoglu, Thomas D Pfister

Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of therapeutic proteins by inhalation--worker safety aspects.
Thomas Pfister, David Dolan, Joel Bercu, Janet Gould, Bonnie Wang

Ann Occup Hyg· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the elusive sites of tyrosyl radicals in cytochrome c peroxidase: implications for oxidation of substrates bound at a site remote from the heme.
Kyle D Miner, Thomas D Pfister, Parisa Hosseinzadeh, Nadime Karaduman, Lynda J Donald

Biochemistry· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Olivier Sitbon, Marion Delcroix, Emmanuel Bergot, Anco B Boonstra, John Granton, Thomas Pfister

Am Heart J· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.
Franziska Boess, Cristina Bertinetti-Lapatki, Sannah Zoffmann, Catherine George, Thomas Pfister

J Mol Endocrinol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis